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Scientific background and hypothesis
In accordance with the statistical data reported by WHO,
liver malignancies are far from the leading incidence
among all cancers (Figure 1) but represent the 3rd most
fatal cancer type causing about 0,7 million deaths annually
[1]. This discrepancy argues for a low efficacy of currently
applied treatments. The consequent economical burden is
unproportionally high, when the modest incidence of this
cancer type is considered in the overall context of health-
care. Our hypothesis comprises possible reasons for the
failure of long-term outcomes. On one side that may be
the divergent origins of the liver cancer provoked by:
➣ hepatitis C
➣ cirrhosis of the liver abused with alcohol
consumption
➣ heterogenic metabolic liver dysfunctions such as
steatosis hepatis, etc.
➣ chronic inflammatory processes of different origin
➣ genetic predisposition
➣ toxic environment
all by its own way leading to primary liver carcinomas
to be discriminated from completely different origin of
the liver metastatic disease down-stream towards several
cancer types primarily developed in colon, stomach,
breast, prostate, pancreas, cervix, bronchus, skin, etc.
On the other side this is the patient individuality as a
kind of “complex biochemical reactor”, which strongly
influences the disease onset and therapy outcomes.
Hence, there are evident deficits in predictive molecular
diagnostics and treatments tailored to the person to be
considered for the field promotion.
Material and methods
One hundred and six patients with primary liver malig-
nancies and secondary liver metastatic disease have been
recruited for a pilot study. The patients have been
grouped according to a gender, type of primary tumour
and an applied therapy (chemotherapy, TACE versus irra-
diation, SIRT). Blood samples have been taken before
therapy, 1 day, 3 and 6 months after the therapy applica-
tion. Each sample with full blood underwent immediate
isolation of plasma and circulating leukocytes which got
frozen and stored at -80°C for consequent analytical pro-
cedure. Individual as well as subgroup specific molecular
profiles have been created using conventional technolo-
gies of clinical proteomics and sub-cellular imaging by
quantitative “comet assay” analysis.
Results interpretation and conclusions
Our results confirm the hypothesis concerning the diver-
gent molecular profiles in corresponding subgroups. As
proposed, all the above listed parameters strongly influ-
ence both the initial profiles before the therapy application
and the reaction towards the applied therapy. Further, the
molecular patterns are characteristic for each group cre-
ated accordingly to the above nominated criteria. The
most characteristic patterns have been identified for
➣ detoxification pathways
➣ microfilamental-network associated proteins
➣ stress proteome
➣ tissue remodelling enzymatic complex
➣ DNA fragmentation (comet patterns)
The principle of individual radiation sensitivity has
been found to be the decisive parameter for choosing
between SIRT and TACE.
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Recommendations
Large-scaled studies are highly recommended to validate
preliminary results of the pilot study. Potential out-
comes might be of highest value for developing of pre-
dictive diagnostics and personalisation of medical
services in the cohort of patients with liver cancer.
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Figure 1 The WHO Regions for Europe and the Americas had the highest incidence of all types of cancer combined for both sexes. Countries in
the WHO Eastern Mediterranean Region had the lowest incidence rates. Among the WHO Regions, the countries in the WHO Western Pacific
Region had by far the highest incidence of stomach cancer and liver cancer. Men in the WHO Western Pacific Region had five times the rate of
liver cancer of men in all other regions, except for Africa, where it was more than double the rate. Women in the WHO Western Pacific Region
also had a considerably higher liver cancer incidence rate than women in other WHO regions [2].
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